Navigation Links
Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain
Date:6/27/2011

LAS VEGAS, June 27, 2011 /PRNewswire/ -- Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, announced today, the Company has completed a sale and revenue collection cycle with a major pharmacy retail chain.  Gamma shipped the Company's energy gel products to a Northeast distribution center for delivery to retail outlets in the New York metropolitan area.  The retail chain has more than 8,000 outlets nationwide.  Gamma's CEO Peter Cunningham noted, "Over the past 2 years, the retail pharmacy sector absorbed the effect of the economic crisis and has started to recover.  With the sector's recovery underway, we have seen renewed interest in Gamma's new technologies and brands nationwide. This interest is paralleled in the supermarket and convenience store channels." He continued, "the credit facility announced in our June 8th 2011 press release will help us fill more orders and address many other retail opportunities."

About Gamma Pharmaceuticals, Inc.

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally.  Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States.  Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action "You've made a brilliant choice for your nutrition;"  SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ a high performance supplement featuring the call to action, "Get Your Gamma On."  Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market.  A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States.  Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms; that give consumers a more pleasant experience.  Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great.  Market categories Gamma targets are growing as rapidly as 60% per year.  Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products.  Gamma also develops and manufactures house brands for major retailers.  At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Gamma Pharmaceuticals, Inc.
Joe Cunningham, CFO (jcunningham@gammapharma.com)
Direct:  (651) 204 2048
Office:  (702) 989 5262  


'/>"/>
SOURCE Gamma Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
3. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
4. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
5. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
6. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
7. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. U.S. FDA Issues Action Letter for Sugammadex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... 2017 The Galien Foundation announced today ... USA Award Nominees. Counted among the global health ... outstanding biomedical and technology product achievement that improves the human ... each candidate must be U.S. Food and Drug Administration (FDA) ... tremendous potential to impact human health. Sales data are not ...
(Date:7/24/2017)... 24, 2017 IBM (NYSE: IBM ) has ... for Solid-State Arrays (SSA) for the fourth year in a ... to Gartner, "Vendors in the Leaders quadrant have the highest ... A vendor in the Leaders quadrant has the market share, ... acceptance of new technologies. These vendors demonstrate a clear understanding ...
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July 21, 2017 ... ) announced today that it will report its second ... Thursday, July 27, 2017. ... July 27, 2017, at 9:00 a.m. Eastern Time.  The ... dialing 1-970-315-0533.  A rebroadcast of the teleconference will be ...
Breaking Medicine Technology:
(Date:7/27/2017)... OH (PRWEB) , ... July 27, 2017 , ... ... Electronic Visit Verification to State Medicaid programs, Managed Care Organizations and Home Care ... 2017. , The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies ...
(Date:7/27/2017)... ... July 27, 2017 , ... MAP ... in this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from ... category of Population Health Management/Patient Engagement Solutions. , MAP was selected as ...
(Date:7/26/2017)... ... July 26, 2017 , ... An inventor from Salisbury, N.C., knows ... yet seen an effective and dignified way to keep leeches in place during therapy," ... , This invention provides an effective way to keep a leech in place on ...
(Date:7/26/2017)... ... ... A major challenge many labs face is a direct result from a ... dry cycle are a few common challenges that can overcome when following best practices. ... and advancements in laboratory freeze dryers that will improve quality and reduce the time ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... on-premises, off and in the cloud ; today announced the availability of its ... within a simple to use control console for Data Discovery, Classification, Encryption and ...
Breaking Medicine News(10 mins):